The emergence of medications like copyright and Semaglutide signifies a major shift in how we treat metabolic disorders. These new therapies belong to a class known as GLP-1 action agonists, which duplicate the effects of a natural hormone that regulates glucose levels and food intake. First, developed for diabetic conditions, their effectiveness i